Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: A final update

European Urology

Volumn 42, Issue 2, 2002, Pages 139-146

  de Reijke, Theo M ^a   Derobert, Eric ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Hormonal treatment; MAB; Prognostic factors; Prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; IMIDAZOLIDINE DERIVATIVE; NILUTAMIDE; ALKALINE PHOSPHATASE; ANDROGEN; PLACEBO;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FACTORIAL ANALYSIS; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; ORCHIECTOMY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME; ADULT; ADVANCED CANCER; BONE METASTASIS; CANCER PAIN; CANCER SURVIVAL; CASTRATION; DRUG EFFECT; DRUG EFFICACY; EUROPE; EVALUATION; HORMONAL THERAPY; HUMAN TISSUE; HYDRONEPHROSIS; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FACTOR ANALYSIS, STATISTICAL; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; MALE; MIDDLE AGED; ORCHIECTOMY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; HUMAN; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 0036668368     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00272-5     Document Type: Article

References (32)

1. New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen
2. DHT in prostate cancer tissue-a guide to management and therapy
3. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
4. A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer
5. A phase III trial of Zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate
6. Maximum androgen blockade using LHRH agonist Buserelin in combination with short-term (2 weeks) or long term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group trial 30843
7. A multicenter randomized trial comparing the luteinizing hormone releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer
8. A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol
9. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853)
10. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients
11. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials
12. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial
13. Long- term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization
14. The prognostic value of histological grading and mean nuclear volume in human prostatic cancer
15. Prognostic factors in prostate cancer
16. Prognostic factors in patients with metastatic (stage D2) prostate cancer: Experience from the Scandinavian Prostatic Cancer Group Study-2
17. Facteurs pronostiques du cancer de la prostate. Revue de la littérature et perspectives d'avenir
18. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters
19. Expression of the cellular adhesion molecule Ecadherin is reduced or absent in high-grade prostate cancer
20. Metastatic diversity in human prostatic carcinoma: Implications of growth factors and growth factor receptors for the metastatic phenotype
21. Analysis of prognostic factors in men with metastatic prostate cancer
22. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer
23. Analysis of prognostic factors in disseminated prostatic cancer. An update
24. Predictive initial parameters for response of stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin
25. Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: Results from a randomized study comprising 150 patients treated wth orchiectomy or estrogens
26. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: Results from two European Organization for Research on Treatment of Cancer trials
27. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer
28. Total androgen blockade for metastatic cancer of the prostate
29. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
30. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials
31. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using non-steroidal anti-androgens
32. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial